Fame and Mortality: Evidence from a Retrospective Analysis of Singers
November 26, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Revuforj
Synonyms :
revumenib
Class :
Menin Inhibitors
Brand Name :
Revuforj
Synonyms :
revumenib
Class :
Menin Inhibitors
Adult
Tablet
25 mg
110 mg
160 mg
Tablet
25 mg
110 mg
160 mg
Menin inhibitor disrupts complex formation between menin and KMT2A fusion proteins to inhibit activation of leukemogenic transcriptional pathway in leukemia.
Menin-KMT2A complex promotes normal blood cell development in leukemia cells with KMT2A fusion proteins.
Frequency defined:
>50%
All grades
Hemorrhage
Nausea
>10-50%
All grades
Phosphate increased
Febrile neutropenia
ALT increased
Musculoskeletal pain
Infection
AST increased
Parathyroid hormone increased, intact
Phosphate decreased
Triglycerides increased
Bacterial infection
QT prolonged on ECG
Viral infection
Fatigue
Alkaline phosphatase increased
Potassium decreased
Decreased appetite
Constipation
Creatinine increased
Calcium increased, corrected
Grade 3 or 4
Infection
Bacterial infection
Febrile neutropenia
Differentiation syndrome
1-10%
All grades
Thrombosis
Grade 3 or 4
Decreased appetite
Musculoskeletal pain
Fatigue
Nausea
Potassium decreased
Viral infection
Thrombosis
AST increased
Constipation
ALT increased
Triglycerides increased
Revumenib has a black box warning for differentiation syndrome, a serious condition linked to targeted therapies for AML. Leukemic cell differentiation causes syndrome with inflammatory cytokines effects.
Contraindications:
None
Cautions:
Neutropenia or thrombocytopenia
Embryo-fetal toxicity
Leukocytosis
Pregnancy Warnings:
Pregnancy category: N/A
Lactation: Excretion of the drug into the human breast milk is unknown
Pregnancy categories:
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.
Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.
Category N: There is no data available for the drug under this category.
Pharmacology:
Revumenib downregulates leukemia programs through menin-MLL1 interaction, differentiates cells, and decreases proliferation capacity. It disrupts critical leukemic cell survival and proliferation genes.
Pharmacodynamics:
It disrupts leukemogenic gene transcription hinders leukemic cell survival. It decreases oncogenic transcription programs and encourages leukemic blast differentiation into non-leukemic blood cells.
Pharmacokinetic:
Absorption:
It has good oral bioavailability.
Distribution:
It has large volume of distribution of 78 L.
Metabolism:
It is metabolized through CYP3A4 pathway.
Excretion and elimination:
It shows apparent clearance of 7 L/hr to 27 L/hr.
It is available in tablet form for oral use.
Generic Name: revumenib
Why do we use revumenib?
Revuforj is latest FDA approved drug indicated in the treatment of acute leukemia.
It is effective with KMT2A gene translocation in adults and children ≥1 year old after standard treatments.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
